科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Neurology2025-12-12· Progressive supranuclear palsy

Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease

Cheng‐Hsuan Li, Sung‐Pin Fan, Pin‐Shiuan Chen, Yung‐Yee Chang, Min‐Yu Lan, Yih-Ru Wu, Ing‐Tsung Hsiao, Han Lin Chiang, Chun‐Yu Chen, Tsung-Lin Lee, Hsiu-Chen Chang, Chiung-Chih Chang, Jung‐Lung Hsu, Chi-Wei Huang, Chin‐Song Lu, Chin‐Hsien Lin

原始摘要(英文原文)· Original abstract
BACKGROUND AND OBJECTIVES: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy neurodegenerative disorder that presents with parkinsonism features and is often indistinguishable from Parkinson disease (PD) in the early stages. The potential of plasma levels of phosphorylated tau (pTau) to differentiate PSP from PD remains unclear. The aim of this study was to identify noninvasive, cost-effective alternatives to tau PET imaging for differentiating PSP from PD. METHODS: F-florzolotau PET imaging, was also recruited. RESULTS: < 0.0001). DISCUSSION: The combination of plasma pTau217 and NfL with brain MRI represents a noninvasive and clinically feasible strategy for distinguishing PSP from PD.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease — 科研速览 Science Skim